Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.
Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study / Frantellizzi, Viviana; Monari, Fabio; Mascia, Manlio; Costa, Renato; Rubini, Giuseppe; Spanu, Angela; Farcomeni, Alessio; Lodi Rizzini, Elisa; Cindolo, Luca; Licari, Maria; Lavelli, Valentina; Nuvoli, Susanna; Ricci, Maria; Dionisi, Valeria; Nappi, Anna Giulia; De Vincentis, Giuseppe. - In: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. - ISSN 0955-3002. - (2020), pp. 1-6. [10.1080/09553002.2020.1838655]
Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study
Frantellizzi, Viviana
Primo
;Mascia, Manlio;Farcomeni, Alessio;De Vincentis, GiuseppeUltimo
2020
Abstract
Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.| File | Dimensione | Formato | |
|---|---|---|---|
|
Frantellizzi_Overall survival_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.34 MB
Formato
Adobe PDF
|
2.34 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
